NKTR

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

0.8217

Open

0.750

VWAP

0.76

Vol

1.73M

Mkt Cap

137.85M

Low

0.720

Amount

1.31M

EV/EBITDA(TTM)

Total Shares

184.02M

-114.57M

EV/OCF(TTM)

P/S(TTM)

1.58

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

15.92M

-26.45%

16.03M

-31.77%

15.94M

-33.94%

Estimates Revision

The market is revising Downward the revenue expectations for Nektar Therapeutics (NKTR) for FY2025, with the revenue forecasts being adjusted by -19.85% over the past three months. During the same period, the stock price has changed by -6.84%.

Revenue Estimates for FY2025

Revise Downward

-19.85%

In Past 3 Month

Stock Price

Go Down

-6.84%

In Past 3 Month

8 Analyst Rating

520.90% Upside

Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 4.92 USD with a low forecast of 2.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

1 Sell

Moderate Buy

520.90% Upside

Current: 0.792

Low

2.00

Averages

4.92

High

7.00

520.90% Upside

Current: 0.792

Low

2.00

Averages

4.92

High

7.00

Jefferies

Roger Song

Hold

Strong Buy

Upgrades

$1 → $2

2025-04-11

Reason

Jefferies

Roger Song

Price Target

$1 → $2

2025-04-11

Upgrades

Hold

Strong Buy

Reason

Jefferies upgraded Nektar to Buy from Hold with a price target of $2, up from $1. The company's rezpegaldesleukin will report topline results for the Phase 2b study in atopic dermatitis in Q2, the analyst tells investors in a research note. The firm expects an "encouraging" efficacy and safety profile with a novel mechanism of action versus available and pipeline comps in atopic dermatitis. It believes the stock's probability skewed reward/risk on the data readout is favorable based on Nektar's current negative enterprise value.

Oppenheimer

Jay Olson

Hold

Buy

Upgrades

2025-03-14

Reason

Oppenheimer

Jay Olson

Price Target

2025-03-14

Upgrades

Hold

Buy

Reason

Oppenheimer upgraded Nektar to Outperform from Perform with a $6 price target.

HC Wainwright & Co.

Arthur He

Strong Buy

Reiterates

$6.5

2025-03-13

Reason

HC Wainwright & Co.

Arthur He

Price Target

$6.5

2025-03-13

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Arthur He

Strong Buy

Reiterates

$6.5

2025-01-13

Reason

HC Wainwright & Co.

Arthur He

Price Target

$6.5

2025-01-13

Reiterates

Strong Buy

Reason

B. Riley Securities

Mayank Mamtani

Strong Buy

Initiates

2025-01-08

Reason

B. Riley Securities

Mayank Mamtani

Price Target

2025-01-08

Initiates

Strong Buy

Reason

B. Riley initiated coverage of Nektar with a Buy rating and $4 price target.

Piper Sandler

Yasmeen Rahimi

Buy

Initiates

2024-11-04

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

2024-11-04

Initiates

Buy

Reason

Piper Sandler initiated coverage of Nektar with an Overweight rating and $7 price target. The analyst believes Nektar's lead asset rezpegaldesleukin has a differentiated IL-2Ralpha mechanaism of action that selectively stimulates tregs. The firm has a high probability of success for rezpegaldesleukin, saying the Phase 1b atopic dermatitis trial demonstrated robust efficacy and safety and validated the utility of targeted treg stimulation.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nektar Therapeutics (NKTR.O) is -1.14, compared to its 5-year average forward P/E of -3.32. For a more detailed relative valuation and DCF analysis to assess Nektar Therapeutics 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.32

Current PE

-1.14

Overvalued PE

-0.88

Undervalued PE

-5.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.44

Current EV/EBITDA

-0.54

Overvalued EV/EBITDA

0.04

Undervalued EV/EBITDA

-4.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

12.35

Current PS

2.26

Overvalued PS

24.48

Undervalued PS

0.22